***Background.*** In the era of widespread electronic health records, a semi-automated surveillance tool could reduce the time and manual effort required to screen patients for central line-associated blood stream infection (CLABSI).

***Methods.*** Carefusion\'s MedMined is an automated surveillance tool that flags potential healthcare associated infections via the Nosocomial Infection Marker (NIM). We sought to determine the positive predictive value (PPV) of the blood NIM and to determine its association with outcomes of mortality, length of stay (LOS), and cost. We reviewed records of 237 patients with blood NIMs using a gold standard of the National Healthcare Safety Network (NHSN) definition for primary BSI. We developed a propensity model to predict the probability of blood NIM during hospitalization. We matched cases with up to 5 non-cases by propensity score and exposure time. We estimated the attributable mortality, LOS, and cost impacts of NHSN-reportable CLABSI and non-NHSN-reportable BSI (i.e., not reportable because no central line or secondary to another infection) compared to non-cases.

***Results.*** Among patients with central lines present, the PPV of the blood NIM for CLABSI was 74.2%. For all patients (with or without central lines), the PPV for BSI was 53.6%. 77% of the \'false positive\' NIMs met criteria for NHSN-defined infection other than BSI. The table shows outcomes associated with blood NIMs vs matched non-cases.

***Conclusion.*** Although many of the cases detected by the tool were not NSHN-reportable, they were associated with adverse outcomes and higher costs, suggesting that detecting them may be an important component of a quality and cost containment program.

###### 

Outcomes for NHSN Reportable and Non-Reportable Cases Compared to Matched Non-Cases

                                      BSI                         Propensity and Exposure Matched Non-Cases   P-value
  ----------------------------------- --------------------------- ------------------------------------------- ----------
  **NHSN-Reportable CLABSI**                                                                                  
  n                                   57                          276                                         
  Mortality, % (n)                    17.5% (10)                  9.4% (26)                                   0.0976
  LOS, Median (Q1, Q3), days          21 (11, 30)                 16 (11, 24)                                 0.0298
  Total Charge, Median (Q1, Q3), \$   143,935 (89,794, 257,447)   115,267 (74,937, 173,053)                   0.0098
  Days to NIM, Mean (SD), days        11.5 (8.4)                                                              
  **Non- Reportable BSI**                                                                                     
  n                                   89                          445                                         
  Mortality, % (n)                    23.6% (21)                  6.7% (30)                                   \<0.0001
  LOS, Median (Q1, Q3), days          14 (9, 20)                  10 (6, 17)                                  0.0001
  Total Charge, Median (Q1, Q3), \$   86,927 (54,728, 156,669)    62,929 (36,743, 115,693)                    \<0.0001
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